Recent Updates
Recently added Catalysts
HRTX Positive Sentiment

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Monday, July 27, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Heron Therapeutics has announced a conference call to discuss its second quarter 2026 financial results, scheduled for August 10, 2026. The call will take place at 8:30 a.m. and will be accessible via live webcast. This event reflects the company's commitment to keeping stakeholders informed about its financial performance.
Price reaction · baseline $0.4558 (2026-07-24 close) · hit pre-market · clean, no other HRTX news in the window
day 0 close
+0.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Heron Therapeutics is actively engaging with investors.
  • The company is preparing to share its financial performance.
  • The scheduled conference call indicates transparency and communication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
8.7%
average across 7 past catalysts
Cash runway
~63 mo
Minimal dilution risk
Lead asset
HTX-011A
Phase 2 · Postoperative Pain

Full Press Release Details

CARY, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, August 10, 2026, at 8:30 a.m.

Frequently Asked Questions

When will Heron Therapeutics report its Q2 2026 results?

Heron Therapeutics will report its Q2 2026 results on August 10, 2026.

What time is the conference call for Q2 2026 results?

The conference call is scheduled for 8:30 a.m. on August 10, 2026.

How can I access the Heron Therapeutics conference call?

The conference call will be available via live webcast.

What is the significance of the conference call?

The call reflects Heron Therapeutics' commitment to transparency with investors.

ShareAdd on Google
Tags: HRTX Viatris Investor Conferences Healthcare Heron Therapeutics financial results conference call biotechnology
Last updated: Jul 27, 2026

Biotech snapshot

Cash runway
$43M liquidity · $1M/mo burn
~63 mo
Minimal dilution risk
Lead asset
HTX-011APhase 2
Postoperative Pain →

Catalyst track record

+23%
best trade around HRTX's most recent catalyst

Peak hindsight return over a 120-day window, across 7 tracked FDA/PDUFA catalysts for HRTX.

See every catalyst's timing & PoA →